Navigation Links
Phase 3 Results Show Canagliflozin as Add-On Therapy to Metformin and Pioglitazone Significantly Lowers Blood Sugar Levels in Adult Patients with Type 2 Diabetes
Date:11/9/2012

research, and these results further support the efficacy and safety profile of canagliflozin," said Kirk Ways, M.D., Ph.D., Vice President and Compound Development Team Leader for canagliflozin at Janssen. "The data are in line with the Phase 3 results announced earlier this year at the annual meetings of the American Diabetes Association and European Association for the Study of Diabetes which suggest that canagliflozin could help control blood glucose in a wide range of patients with type 2 diabetes, including patients on other antihyperglycemic medications such as pioglitazone and metformin."

These results are included in the abstract, "Efficacy and Safety of Canagliflozin in Subjects with Type 2 Diabetes on Metformin and Pioglitazone" (board #64). An additional abstract, "Efficacy and Safety of Canagliflozin in Subjects with Type 2 Diabetes with Moderate Renal Impairment" (board #75) will also be presented at CODHy 2012.

About Canagliflozin

Canagliflozin is an investigational sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of patients with type 2 diabetes. The kidneys of people with type 2 diabetes reabsorb greater amounts of glucose back into the body compared to non-diabetic people, which may contribute to elevated glucose levels. Canagliflozin blocks the reabsorption of glucose by the kidney, increasing glucose excretion and lowering blood glucose levels.

The global Phase 3 canagliflozin clinical program, which enrolled 10,285 patients in nine studies, is the largest late-stage development program for an investigational pharmacologic product for the treatment of type 2 diabetes submitted to health authorities to date. The program evaluated the safety and efficacy of canagliflozin across the spectrum of type 2 diabetes management, from adult patients treated only with diet and exercise to those requiring insulin injections to maintain glycemic control, and in three large studies in special populations: older p
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Mallinckrodt plc (NYSE: MNK ) ... a share repurchase program. The open-ended authorization permits the ... plc ordinary shares. "Funding additional initiatives ... as we continue to pursue a range of focused ...
(Date:1/22/2015)... a privately held medical device company, announced today that ... ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to sell ... cancer in Japan . ViewRay,s technology, ... only MRI-guided radiation therapy system that images and treats ...
(Date:1/22/2015)... , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... focus on Omega-3 therapies for cardiovascular disease and overall health ... Company,s accomplishments in 2014 and its outlook for 2015 from ... Fellow Shareholders, We would like to take this ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... Prevention and Control Professionals Cite,Greatest Needs for ... More Environmental Services and Time-Saving High Tech ... than three out of four,(76%) infection prevention ... implemented additional measures to prevent the,transmission of ...
... Inc.,(Nasdaq: TRBN ) today announced presentation ... of Rheumatology meeting in Paris demonstrating that,repeat ... the,treatment of rheumatoid arthritis (RA), continues to ... Rheumatology (ACR) criteria and,consistent pharmacodynamic (PD) effects. ...
Cached Medicine Technology:Nationwide Progress Poll Reveals Increased Efforts by Hospitals to Control MRSA Infection 2Nationwide Progress Poll Reveals Increased Efforts by Hospitals to Control MRSA Infection 3Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting 2Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting 3Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting 4Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting 5
(Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
(Date:1/22/2015)... January 22, 2015 The federal court overseeing ... U.S. District Court, Southern District of West Virginia has upheld ... that proceeding’s first bellwether trial. In an Order dated January ... trial after finding that C.R. Bard had not proven a ...
(Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... annual revenues in the past three years. Today, the business ... , According to the sales manager of the company, this ... in 2015. This point can be reflected on the discounted ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 As ... of overall health care gains momentum worldwide, Rev. Eric ... HealthCare Chaplaincy Network (HCCN), will be the keynote ... spiritual care in Israel’s public health system. , The conference, ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... Scientists at Washington University School of Medicine in St. ... collection of proteins associated with the formation of actin ... cell,s ability to move is important to a broad ... cells pursue disease-causing invaders and how metastasizing cancer cells ...
... Donated, freeze-dried tendon grafts loaded with gene therapy ... a goal that has eluded surgeons to date. ... journal Molecular Therapy, a new graft technique may ... tendon tissue can reorganize as it heals. Such ...
... and improves ... customer ... subsidiary of Hays plc., one of the world,s leading specialist,recruitment ... processes and improve customer service., Hays stated that it ...
... in Bangalore, SUNNYVALE, Calif., Jan. 8 ... in the field of radiosurgery,announced today that Healthcare ... System for its new oncology center in,Bangalore, India. ... the first,CyberKnife System in India, expanding treatment access ...
... 8 Isolagen(TM), Inc. (Amex: ILE ),announced today ... Executive Officer of Isolagen, will present at the 26th ... 2:00 p.m.,(Pacific Time) / 11:00 a.m. (Eastern Time). The ... in San Francisco, California., The presentation will be ...
... Innovation with Beauty and Fitness Benefits From Too Faced ... Cosmetics and FUZE ... keeping beauty and,diet resolutions on track with a lip gloss that ... Faced FUZE Slenderize Guilt,Free Gloss! The first lip gloss on the ...
Cached Medicine News:Health News:Insights into cell movement likely to aid immune study, cancer research 2Health News:Insights into cell movement likely to aid immune study, cancer research 3Health News:Freeze-dried tendon implants prove effective in early studies 2Health News:Freeze-dried tendon implants prove effective in early studies 3Health News:Freeze-dried tendon implants prove effective in early studies 4Health News:Freeze-dried tendon implants prove effective in early studies 5Health News:Hays AG Integrates Authentidate(R) Signature Solution for Electronic Invoicing 2Health News:Hays AG Integrates Authentidate(R) Signature Solution for Electronic Invoicing 3Health News:Hays AG Integrates Authentidate(R) Signature Solution for Electronic Invoicing 4Health News:CyberKnife Radiosurgery Expands to India 2Health News:CyberKnife Radiosurgery Expands to India 3Health News:Isolagen Inc. to Present at the 26th Annual JPMorgan Healthcare Conference 2Health News:NEW! Too Faced FUZE Slenderize Guilt Free Gloss 2
The Hybrid Fixator consists of Three basic components: rings, wires, clamps. Final fracture reduction can be easily performed after frame assembly....
... pelvic fractures is one of the most ... surgeons. , ,Recognizing the difficulties when using ... internal fixation in these types of emergencies, ... a method to provide emergent reduction and ...
... external fixator designed for the quick stabilization ... humerus and forearm. , ,Indications include open ... the treatment of choice due to soft ... fully compatible with the Ace-Fischer System. The ...
... Stabilization with the Orthofix Pelvic Fixator ... inserted into the pelvis, and a fixator ... joined by a connector unit. A supplementary ... or in iliac crest applications. With this ...
Medicine Products: